Insider Transaction Report for Agios Pharmaceuticals, Inc.

Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, Inc., reported a disposition of 3,000 performance share units and an acquisition of 3,000 restricted stock units on June 18, 2026. The performance share units, representing contingent rights to common stock, were disposed of with a post-transaction balance of 9,000 units. The acquisition of restricted stock units resulted in a post-transaction balance of 3,000 units. Both transactions had a price per share of 0.00 and were settled with underlying common stock. The performance stock units vest upon achievement of specified milestones, with one milestone met as of June 18, 2026, and vesting scheduled for December 31, 2027, contingent on continued service. The restricted stock units also represent contingent rights to common stock.